<< Return to previous page

Respiratory Formulary Update

  • What is it:  New Asthma Inhalers
  • Of interest to: All Clinical staff


AirFluSal MDI and Aerivio Spiromax have been added to the formulary for the management of asthma.

  • AirFluSal MDI is a metered dose inhaler with the combination of salmeterol and fluticasone indicated for the regular treatment of asthma where a long acting B2 agonist and inhaled corticosteroid is indicated. It is licensed in patients aged 18 years and above only. It is available in 2 strengths of 25/125mcg and 25/250mcg.
  • Aerivio Spiromax is a dry powder inhaler which also a combination of salmeterol and fluticasone at the 50/500mcg strength. It is to be used on the management of severe asthma where the lower strengths of ICS and LABA combinations are not adequately controlling asthma.


A summary of the inhaled corticosteroids and long acting beta agonists approved for use across east Kent in adults is available here.